Education
About Us
Working with TipRanks
Follow Us
ProQR (PRQR)
NASDAQ:PRQR
PRQR Stock Chart & Stats
$1.68
-$0.10(-3.77%)
At close: 4:00 PM EST
$1.68
-$0.10(-3.77%)
Day’s Range― - ―
52-Week Range$1.07 - $3.10
Previous CloseN/A
Volume75.97K
Average Volume (3M)534.76K
Market Cap
$176.76M
Enterprise Value$91.96M
Total Cash (Recent Filing)$106.88M
Total Debt (Recent Filing)$16.49M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Feb 19, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding105,212,524
10 Day Avg. Volume796,312
30 Day Avg. Volume534,757
Financial Highlights & Ratios
PEG Ratio2.63
Price to Book (P/B)2.36
Price to Sales (P/S)11.05
P/FCF Ratio-5.53
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue5.91
Enterprise Value/Gross Profit5.91
Enterprise Value/Ebitda-2.43
Forecast
1Y Price Target
$7.60Price Target Upside352.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform Validation And PartnershipFirst-in-human Axiomer data together with an Eli Lilly collaboration could validate the RNA editing platform, boosting credibility and enabling expansion into fibrosis, metabolic, and neurology indications.
Regulatory Pathway ClarityRegulatory precedent from nebokitug and approvals of bile-acid transport therapies suggests that bile acid biomarkers and hard clinical endpoints can be accepted by regulators, clarifying a feasible approval path for AX-0810.
Therapeutic Mechanism & Unmet NeedAX-0810 blocks the NTCP bile-acid uptake channel to reduce toxic intracellular bile acid accumulation in silent primary sclerosing cholangitis, targeting a clear unmet clinical need supported by human genetics evidence.
Bears Say
Durability UncertaintyLong-term durability of RNA editing remains unproven and may require extended follow-up to confirm a sustained therapeutic effect, creating execution risk for AX-0810.
Immunogenicity And Safety RiskPotential immune activation from RNA editing could lead to safety concerns that necessitate additional studies or limit dosing, increasing development risk and costs.
Post-treatment Monitoring BurdenRequirement for prolonged monitoring to demonstrate durable effects and rule out immune activation may slow clinical development, complicate trial design, and delay broader patient adoption.
ProQR News
PRQR FAQ
What was ProQR’s price range in the past 12 months?
ProQR lowest stock price was $1.07 and its highest was $3.10 in the past 12 months.
What is ProQR’s market cap?
ProQR’s market cap is $176.76M.
When is ProQR’s upcoming earnings report date?
ProQR’s upcoming earnings report date is Feb 19, 2026 which is in 36 days.
How were ProQR’s earnings last quarter?
ProQR released its earnings results on Nov 06, 2025. The company reported -$0.116 earnings per share for the quarter, beating the consensus estimate of -$0.118 by $0.001.
Is ProQR overvalued?
According to Wall Street analysts ProQR’s price is currently Undervalued.
Does ProQR pay dividends?
ProQR does not currently pay dividends.
What is ProQR’s EPS estimate?
ProQR’s EPS estimate is -0.12.
How many shares outstanding does ProQR have?
ProQR has 105,212,524 shares outstanding.
What happened to ProQR’s price movement after its last earnings report?
ProQR reported an EPS of -$0.116 in its last earnings report, beating expectations of -$0.118. Following the earnings report the stock price went down -7.143%.
Which hedge fund is a major shareholder of ProQR?
Currently, no hedge funds are holding shares in PRQR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProQR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.60 (352.38% Upside)
$7.60 (352.38% Upside)
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.08%
12-Months-Change
Fundamentals
Return on Equity
-99.45%
Trailing 12-Months
Asset Growth
27.61%
Trailing 12-Months
Company Description
ProQR
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
PRQR Stock 12 Month Forecast
Average Price Target
$7.60
▲(352.38% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.78% Mutual Funds
26.03% Other Institutional Investors
71.82% Public Companies and
Individual Investors